Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections
A fosfomycin plus tobramycin combination formulation for delivery by aerosolization is described. The concentrated fosfomycin tobramycin combination formulation containing an efficacious amount of fosfomycin plus tobramycin is able to inhibit susceptible bacteria. Fosfomycin and tobramycin are formulated separately in a dual ampoule such that when reconstituted, the pH is between 4.5 and 8.0 or as a dry powder. The method for treatment of respiratory tract infections by a formulation delivered as an aerosol having a mass median aerodynamic diameter predominantly between 1 to 5μ, produced by a jet or ultrasonic nebulizer (or equivalent) or dry powder inhaler.
1. An aerosol formulation consisting of from about 1 to about 300 mg of fosfomycin and from about 1 to about 300 mg of tobramycin in a physiologically acceptable solution wherein the weight ratio is about 8 parts by weight of fosfomycin to about 2 parts by weight of tobramycin, wherein said formulation is suitable for administration by a nebulizer.
2. The aerosol formulation according to claim 1 , wherein the physiologically acceptable solution comprises from about 0.5 to about 7 mL of solution containing a chloride concentration of >30 mM.
3. A dry powder formulation consisting of from about 1 to about 300 mg of fosfomycin and from about 1 to about 300 mg of tobramycin and at least one pharmaceutically acceptable excipient wherein the weight ratio is about 8 parts by weight of fosfomycin to about 2 parts by weight of tobramycin, wherein said formulation is to be administered using a dry powder inhaler.